InsightfulValue
← Home

Gilead Sciences
Gilead Sciences

Pharma / Pharma


πŸ”§ Tools

βœ… Due Diligence
Company at a Glance

Gilead Sciences

πŸ“Š Get full analytics about Gilead Sciences

Sign up for free or log in

πŸ“– Get insights from "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" now!

Price
Live  
Overview
Gilead Sciences is an American biopharmaceutical company that focuses on the development and commercialization of innovative medicines for the treatment of life-threatening diseases. The company was founded in 1987 and is headquartered in Foster City, California.
Gilead Sciences is known for its groundbreaking work in the field of HIV/AIDS. In 1996, the company launched its first HIV medication, Viread, which was the first of its kind to be approved by the US Food and Drug Administration (FDA). Since then, Gilead has developed and commercialized other HIV medications, including Truvada, Atripla, and Biktarvy.
In addition to its work in HIV/AIDS, Gilead Sciences has expanded into other areas of medicine, including hepatitis C, liver diseases, and oncology. In 2017, the company acquired Kite Pharma, a leader in the development of personalized cancer therapies, further diversifying its portfolio.
Gilead Sciences has a global presence, with operations in North America, Europe, Asia, and Latin America. The company currently employs over 12,000 people worldwide and has a market capitalization of over $90 billion.
In recent years, Gilead Sciences has faced criticism for the high prices of its medications, particularly for its HIV and hepatitis C treatments. The company has implemented various initiatives to increase access to its medicines for patients in need, including partnerships with generic drug manufacturers and patient assistance programs.
What is special about the company?
Gilead Sciences

πŸ“ˆ Want to read more about Gilead Sciences?

Sign up for free or log in

✍️ Sign up to get "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" for free

MS4gUGlvbm VlcmluZyBS b2xlIGluIE hJVi9BSURT IFRyZWF0bW VudDogR2ls ZWFkIFNjaW VuY2VzIHBs YXllZCBhIG NydWNpYWwg cm9sZSBpbi B0aGUgZGV2 ZWxvcG1lbn Qgb2YgYW50 aXJldHJvdm lyYWwgZHJ1 Z3MgZm9yIH RoZSB0cmVh dG1lbnQgb2 YgSElWL0FJ RFMuIEl0cy BmaXJzdCBk cnVnLCBWaX JlYWQsIHdh cyB0aGUgZm lyc3Qgb25j ZS1kYWlseS wgc2luZ2xl LXRhYmxldC ByZWdpbWVu IGZvciBISV YgdHJlYXRt ZW50LCB3aG ljaCByZXZv bHV0aW9uaX plZCBISVYg dGhlcmFweS 48YnI+Mi4g SW5ub3ZhdG l2ZSBSZXNl YXJjaCBhbm QgRGV2ZWxv cG1lbnQ6IF RoZSBjb21w YW55IGhhcy BhIHN0cm9u ZyBmb2N1cy BvbiByZXNl YXJjaCBhbm QgZGV2ZWxv cG1lbnQgYW 5kIGhhcyBh IHRyYWNrIH JlY29yZCBv ZiBicmluZ2 luZyBpbm5v dmF0aXZlIH RoZXJhcGll cyB0byB0aG UgbWFya2V0 LiBJdCBoYX MgYSByb2J1 c3QgcGlwZW xpbmUgb2Yg ZHJ1Z3MgaW 4gdmFyaW91 cyBzdGFnZX Mgb2YgY2xp bmljYWwgZG V2ZWxvcG1l bnQsIGluY2 x1ZGluZyB0 cmVhdG1lbn RzIGZvciBj YW5jZXIsIG xpdmVyIGRp c2Vhc2VzLC BhbmQgaW5m bGFtbWF0b3 J5IGFuZCBy ZXNwaXJhdG 9yeSBjb25k aXRpb25zLj xicj4zLiBH cm91bmRicm Vha2luZyBI ZXBhdGl0aX MgQyBUcmVh dG1lbnQ6IE dpbGVhZCdz IGJyZWFrdG hyb3VnaCBk cnVnLCBTb3 ZhbGRpLCB3 YXMgdGhlIG ZpcnN0IG9y YWwgdGhlcm FweSBmb3Ig aGVwYXRpdG lzIEMgdGhh dCBvZmZlcm VkIGEgY3Vy ZSBmb3IgdG hlIGRpc2Vh c2UuIEl0IH dhcyBhbHNv IHRoZSBmYX N0ZXN0LXNl bGxpbmcgZH J1ZyBpbiBo aXN0b3J5LC ByZWFjaGlu ZyAkMTAgYm lsbGlvbiBp biBzYWxlcy B3aXRoaW4g aXRzIGZpcn N0IHllYXIg b2YgcmVsZW FzZS48YnI+ NC4gQ29tbW l0bWVudCB0 byBBY2Nlc3 MgYW5kIEFm Zm9yZGFiaW xpdHk6IFRo ZSBjb21wYW 55IGlzIGNv bW1pdHRlZC B0byBwcm92 aWRpbmcgYW NjZXNzIHRv IGl0cyBsaW ZlLXNhdmlu ZyBtZWRpY2 F0aW9ucyB0 byBwYXRpZW 50cyBpbiBu ZWVkIGFyb3 VuZCB0aGUg d29ybGQuIE l0IGhhcyBl c3RhYmxpc2 hlZCBudW1l cm91cyBwcm 9ncmFtcyB0 byBtYWtlIG l0cyBtZWRp Y2F0aW9ucy BhY2Nlc3Np YmxlIGFuZC BhZmZvcmRh YmxlLCBpbm NsdWRpbmcg cHJpY2luZy BhZ3JlZW1l bnRzIHdpdG ggdmFyaW91 cyBjb3VudH JpZXMgYW5k IGEgcGF0aW VudCBhc3Np c3RhbmNlIH Byb2dyYW0g Zm9yIHVuaW 5zdXJlZCBh bmQgdW5kZX JpbnN1cmVk IGluZGl2aW R1YWxzIGlu IHRoZSBVbm l0ZWQgU3Rh dGVzLjxicj 41LiBTdHJv bmcgRmluYW 5jaWFsIFBl cmZvcm1hbm NlOiBHaWxl YWQgU2NpZW 5jZXMgaGFz IGNvbnNpc3 RlbnRseSBk ZWxpdmVyZW Qgc3Ryb25n IGZpbmFuY2 lhbCByZXN1 bHRzLCB3aX RoIGEgc3Rl YWR5IGluY3 JlYXNlIGlu IHJldmVudW UgYW5kIGVh cm5pbmdzLi BJdHMgZmlu YW5jaWFsIH N0YWJpbGl0 eSBhbGxvd3 MgdGhlIGNv bXBhbnkgdG 8gaW52ZXN0 IGluIHJlc2 VhcmNoIGFu ZCBkZXZlbG 9wbWVudCBh bmQgZGl2ZX JzaWZ5IGl0 cyBwb3J0Zm 9saW8uPGJy PjYuIFNvY2 lhbCBSZXNw b25zaWJpbG l0eTogVGhl IGNvbXBhbn kgaXMgY29t bWl0dGVkIH RvIG1ha2lu ZyBhIHBvc2 l0aXZlIGlt cGFjdCBiZX lvbmQgaXRz IHByb2R1Y3 RzLCB3aXRo IGEgZm9jdX Mgb24gc29j aWFsIHJlc3 BvbnNpYmls aXR5IGFuZC BzdXN0YWlu YWJpbGl0eS 4gSXQgaGFz IGluaXRpYX RpdmVzIHRv IHJlZHVjZS BpdHMgZW52 aXJvbm1lbn RhbCBmb290 cHJpbnQsIH Byb21vdGUg ZGl2ZXJzaX R5IGFuZCBp bmNsdXNpdm l0eSBpbiBp dHMgd29ya2 ZvcmNlLCBh bmQgc3VwcG 9ydCBjb21t dW5pdGllcy BpbiBuZWVk Ljxicj43Li BDb3Jwb3Jh dGUgQ3VsdH VyZTogR2ls ZWFkIFNjaW VuY2VzIGlz IGtub3duIG ZvciBpdHMg aW5jbHVzaX ZlIGFuZCBz dXBwb3J0aX ZlIGNvcnBv cmF0ZSBjdW x0dXJlLCB3 aGljaCBwcm 9tb3RlcyBp bm5vdmF0aW 9uLCBjb2xs YWJvcmF0aW 9uLCBhbmQg ZW1wbG95ZW UgZGV2ZWxv cG1lbnQuIF RoZSBjb21w YW55IGhhcy BiZWVuIHJl Y29nbml6ZW Qgd2l0aCBu dW1lcm91cy Bhd2FyZHMg Zm9yIGl0cy B3b3JrcGxh Y2UgY3VsdH VyZSwgaW5j bHVkaW5nIG JlaW5nIG5h bWVkIG9uZS BvZiB0aGUg YmVzdCBwbG FjZXMgdG8g d29yayBmb3 IgTEdCVFEg ZXF1YWxpdH ku
What the company's business model?
Gilead Sciences

πŸ“ˆ Want to read more about Gilead Sciences?

Sign up for free or log in

πŸ“₯ Get our free eBook now: "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

VGhlIEdpbG VhZCBTY2ll bmNlcyBjb2 1wYW55J3Mg YnVzaW5lc3 MgbW9kZWwg aXMgZm9jdX NlZCBvbiBk ZXZlbG9waW 5nIGFuZCBj b21tZXJjaW FsaXppbmcg aW5ub3ZhdG l2ZSBtZWRp Y2luZXMgaW 4gYXJlYXMg b2YgaGlnaC B1bm1ldCBt ZWRpY2FsIG 5lZWQuIFRo aXMgaW5jbH VkZXMgY29u ZHVjdGluZy ByZXNlYXJj aCBhbmQgZG V2ZWxvcG1l bnQgZm9yIH RyZWF0bWVu dHMgb2Ygdm lyYWwsIGxp dmVyLCBpbm ZsYW1tYXRp b24sIGFuZC BvbmNvbG9n eSBkaXNlYX Nlcy4gVGhl IGNvbXBhbn kgYWxzbyBz dHJpdmVzIH RvIGltcHJv dmUgYWNjZX NzIHRvIGl0 cyB0aGVyYX BpZXMgZm9y IHBhdGllbn RzIGFyb3Vu ZCB0aGUgd2 9ybGQsIHdo aWxlIG1haW 50YWluaW5n IGEgc3Ryb2 5nIGZpbmFu Y2lhbCBwZX Jmb3JtYW5j ZSBhbmQgZG VsaXZlcmlu ZyB2YWx1ZS B0byBpdHMg c2hhcmVob2 xkZXJzLiBH aWxlYWQncy BhcHByb2Fj aCBpbmNsdW RlcyBjb2xs YWJvcmF0aW 9ucyBhbmQg cGFydG5lcn NoaXBzIHdp dGggb3RoZX IgY29tcGFu aWVzLCBnb3 Zlcm5tZW50 IGFnZW5jaW VzLCBhbmQg bm9uLXByb2 ZpdCBvcmdh bml6YXRpb2 5zLCBhcyB3 ZWxsIGFzIG ludmVzdG1l bnRzIGluIH Jlc2VhcmNo IGFuZCBkZX ZlbG9wbWVu dCB0byBkaX Njb3ZlciBh bmQgZGV2ZW xvcCBuZXcg dHJlYXRtZW 50cyBhbmQg ZXhwYW5kIH RoZSB1c2Ug b2YgaXRzIG V4aXN0aW5n IHByb2R1Y3 RzLg==
Interesting facts about the company
Gilead Sciences

πŸ“ˆ Want to read more about Gilead Sciences?

Sign up for free or log in

🎁 Free download! "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3MvQz J6NWNNdGdW ek9UZkxzcG hRWEoud2Vi cCIgYWx0PS JHaWxlYWQg U2NpZW5jZX MiIHRpdGxl PSJHaWxlYW QgU2NpZW5j ZXMiICBjbG Fzcz0iaW1n LWZsdWlkIi BoZWlnaHQ9 OTAgd2lkdG g9OTAgbG9h ZGluZz0nbG F6eScgc3R5 bGU9J2Jvcm Rlci1yYWRp dXM6IDZweD snPgoKICAg ICAgICAgIC AgICAgICAg ICA8ZGl2IH N0eWxlPSdm bGV4OiAxOy B0ZXh0LWFs aWduOiBjZW 50ZXI7IG1h cmdpbi1sZW Z0OiA1cHg7 Jz4KICAgIC AgICAgICAg ICAgICAgIC AgICAgPHAg c3R5bGU9J2 ZvbnQtc2l6 ZTogMjZweD sgY29sb3I6 ICMzMzM7IG 1hcmdpbi1i b3R0b206ID E1cHg7Jz4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIPCf k4ggV2FudC B0byByZWFk IG1vcmUgYW JvdXQgR2ls ZWFkIFNjaW VuY2VzPwog ICAgICAgIC AgICAgICAg ICAgICAgIC A8L3A+Cgog ICAgICAgIC AgICAgICAg ICAgICAgIC A8YSBocmVm PSdpbmRleC 5waHA/cGFn ZT1zaWdudX AnIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGJhY2tncm 91bmQtY29s b3I6ICMwMD dCRkY7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBjb2xv cjogI2ZmZj sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIH BhZGRpbmc6 IDEwcHggMj BweDsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIGJvcmRl ci1yYWRpdX M6IDVweDsK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIHRl eHQtZGVjb3 JhdGlvbjog bm9uZTsKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGZvbn Qtd2VpZ2h0 OiBib2xkOw ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgbW FyZ2luLXJp Z2h0OiAxMH B4OwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgdHJhbnNp dGlvbjogYm Fja2dyb3Vu ZC1jb2xvci AwLjNzIGVh c2U7JwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgb25tb3 VzZW92ZXI9 J3RoaXMuc3 R5bGUuYmFj a2dyb3VuZE NvbG9yPSIj MDA1NmIzIi cKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG 9ubW91c2Vv dXQ9J3RoaX Muc3R5bGUu YmFja2dyb3 VuZENvbG9y PSIjMDA3Qk ZGIic+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBTaWdu IHVwIGZvci BmcmVlCiAg ICAgICAgIC AgICAgICAg ICAgICAgID wvYT4KCiAg ICAgICAgIC AgICAgICAg ICAgICAgID xzcGFuIHN0 eWxlPSdtYX JnaW46IDAg OHB4OyBjb2 xvcjogIzU1 NTsnPm9yPC 9zcGFuPgoK ICAgICAgIC AgICAgICAg ICAgICAgIC AgPGEgaHJl Zj0naW5kZX gucGhwP3Bh Z2U9bG9naW 4nIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGNvbG9yOi AjMDA3QkZG OwogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg dGV4dC1kZW NvcmF0aW9u OiB1bmRlcm xpbmU7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBmb250 LXdlaWdodD ogNTAwOyc+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBs b2cgaW4KIC AgICAgICAg ICAgICAgIC AgICAgICAg PC9hPgoKCi AgICAgICAg ICAgICAgIC AgICAgICAg IDxwIHN0eW xlPSdtYXJn aW4tdG9wOi AxNXB4OyBm b250LXNpem U6IDEzcHg7 IGZvbnQtd2 VpZ2h0OiBi b2xkOyBjb2 xvcjogI2Qz MmYyZjsnPg ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAg8J +TnSBKb2lu IHVzIGFuZC BncmFiIHlv dXIgY29weS BvZiA8aT4i VGhlIENoZW NrbGlzdCBW YWx1ZSBJbn Zlc3RvciDi gJQgQSBTbW FydGVyIFdh eSB0byBQaW NrIFN0b2Nr cyI8L2k+Ci AgICAgICAg ICAgICAgIC AgICAgICAg IDwvcD4KCi AgICAgICAg ICAgICAgIC AgICAgICAg IDwhLS0KIC AgICAgICAg ICAgICAgIC AgICAgICAg PGRpdiBzdH lsZT0nbWFy Z2luLXRvcD ogMTJweDsg Zm9udC1zaX plOiAxM3B4 OyBjb2xvcj ogIzQ0NDsn PgogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg U2lnbiB1cC Bub3cgYW5k IGdldCBvdX IgZnJlZSBl Qm9vayAKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIDxiPl RoZSBDaGVj a2xpc3QgVm FsdWUgSW52 ZXN0b3Ig4o CUIEEgU21h cnRlciBXYX kgdG8gUGlj ayBTdG9ja3 M8L2I+CiAg ICAgICAgIC AgICAgICAg ICAgICAgID wvZGl2Pgog ICAgICAgIC AgICAgICAg ICAgICAgIC AtLT4KICAg ICAgICAgIC AgICAgICAg ICAgICAgPC EtLQogICAg ICAgICAgIC AgICAgICAg ICAgICA8ZG l2IHN0eWxl PSdtYXJnaW 4tdG9wOiAx NnB4OyBmb2 50LXNpemU6 IDE0cHg7IG NvbG9yOiAj NDQ0OyBmb2 50LWZhbWls eTogLWFwcG xlLXN5c3Rl bSwgQmxpbm tNYWNTeXN0 ZW1Gb250LC BTZWdvZSBV SSwgUm9ib3 RvLCBIZWx2 ZXRpY2EgTm V1ZSwgc2Fu cy1zZXJpZj sgbGluZS1o ZWlnaHQ6ID EuNjsnPgog ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgSGF2 ZSB5b3UgaG VhcmQgYWJv dXQgb3VyIH Nob3J0IDxz dHJvbmcgc3 R5bGU9J2Zv bnQtd2VpZ2 h0OiA2MDA7 Jz5EYWlseS BWaWRlbyBO ZXdzbGV0dG VyPC9zdHJv bmc+PwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgPGEgaH JlZj0naHR0 cHM6Ly93d3 cuaW5zaWdo dGZ1bHZhbH VlLmNvbS9u ZXdzbGV0dG VyLnBocCcg dGFyZ2V0PS dfYmxhbmsn IHN0eWxlPS djb2xvcjog IzAwN0JGRj sgdGV4dC1k ZWNvcmF0aW 9uOiBub25l OyBmb250LX dlaWdodDog NTAwOyBtYX JnaW4tbGVm dDogNnB4Oy c+CiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgRmlu ZCBvdXQgbW 9yZQogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgPC9hPgog ICAgICAgIC AgICAgICAg ICAgICAgIC A8L2Rpdj4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgLS0+CiAg ICAgICAgIC AgICAgICAg ICAgPC9kaX Y+CiAgICAg ICAgICAgIC AgICA8L2Rp dj4KICAgIC AgICAgICAg PC9kaXY+Ci AgICAgICAg ICAgIAogIC AgICAgIAog ICAgICAgID xzcGFuIGNs YXNzPSdibH VycmVkLXRl eHQnPgogIC AgICAgICAg ICBNUzRnUj Jsc1pXIEZr SUZOamFXVn UgWTJWeklI ZGhjeSBCbW IzVnVaR1Zr IElHbHVJRE U1T0QgY2dZ bmtnVFdsai BhR0ZsYkNC U2FXIDl5Wk dGdUxDQmgg SUcxbFpHbG pZVyB3Z1pH OWpkRzl5IE lHWnliMjBn VG0gVjNJRm x2Y21zdSBJ RlJvWlNCam IyIDF3WVc1 NUlIZGggY3 lCdVlXMWxa QyBCaFpuUm xjaUIwIGFH VWdZbWxpYk cgbGpZV3dn YkdGdSBaQ0 J2WmlCSGFX IHhsWVdRc0 lIZG8gYVdO b0lIZGhjeS BCcmJtOTNi aUJtIGIzSW dhWFJ6SUcg aGxZV3hwYm 1jZyBjSEp2 Y0dWeWRHIG xsY3k0OFlu SSsgTWk0Z1 IybHNaVyBG a0lGTmphV1 Z1IFkyVnpJ R2x6SUcgRW dZbWx2Y0do aCBjbTFoWT JWMWRHIGxq WVd3Z1kyOX QgY0dGdWVT QjBhRyBGME lHWnZZM1Z6 IFpYTWdiMj RnWkcgVjJa V3h2Y0dsdS BaeUJoYm1R Z1kyIDl0Yl dWeVkybGgg YkdsNmFXNW 5JSCBSb1pY SmhjR2xsIG N5Qm1iM0ln YkcgbG1aUz EwYUhKbCBZ WFJsYm1sdV p5IEJrYVhO bFlYTmwgY3 l3Z2QybDBh QyBCaElIQm hjblJwIFkz VnNZWElnWm 0gOWpkWE1n YjI0ZyBTRW xXTDBGSlJG IE1zSUdobG NHRjAgYVhS cGN5QkNJRy BGdVpDQkRM Q0JzIGFYWm xjaUJrYVgg TmxZWE5sY3 l3ZyBiMjVq YjJ4dlozIG tzSUdGdVpD QnkgWlhOd2 FYSmhkRyA5 eWVTQmthWE 5sIFlYTmxj eTQ4WW4gSS tNeTRnVkdo bCBJR052Yl hCaGJuIG5p Z0pseklHWn AgY25OMElH MWhhbSA5eU lHSnlaV0Zy IGRHaHliM1 ZuYUMgQmpZ VzFsSUdsdS BJREU1T1RZ Z2QyIGwwYU NCMGFHVWcg WVhCd2NtOT JZVyB3Z2Iy WWdkR2hsIG FYSWdTRWxX SUggUnlaV0 YwYldWdSBk Q0JrY25Wbk xDIEJXYVhK bFlXUXMgSU hkb2FXTm9J SCBkaGN5Qj BhR1VnIFpt bHljM1FnZE ggSmxZWFJ0 Wlc1MCBJSF J2SUhSaGNt IGRsZENCaG JpQmwgYm5w NWJXVWdZMi BGc2JHVmtJ SEpsIGRtVn ljMlVnZEgg Smhibk5qY2 1sdyBkR0Z6 WlNCMGFHIE YwSUdseklH VnogYzJWdW RHbGhiQyBC bWIzSWdkR2 hsIElISmxj R3hwWTIgRj BhVzl1SUc5 bSBJSFJvWl NCSVNWIFln ZG1seWRYTX UgUEdKeVBq UXVJRSBsdU lESXdNVEVz IElFZHBiR1 ZoWkMgQlRZ MmxsYm1ObC BjeUJoWTNG MWFYIEpsWk NCMGFHVWcg WW1sdmNHaG hjbSAxaFky VjFkR2xqIF lXd2dZMjl0 Y0cgRnVlU3 dnVUdoaCBj bTFoYzNObG RDIHdnWm05 eUlDUXggTV NCaWFXeHNh VyA5dUxpQl VhR2x6IElH RmpjWFZwYz IgbDBhVzl1 SUdKeSBiM1 ZuYUhRZ1Iy IGxzWldGa0 lIUm8gWlNC aWJHOWphMi BKMWMzUmxj aUJrIGNuVm 5MQ0JUYjMg WmhiR1JwTE NCMyBhR2xq YUNCeVpYIF p2YkhWMGFX OXUgYVhwbF pDQjBhRyBV Z2RISmxZWF J0IFpXNTBJ R1p2Y2kgQm 9aWEJoZEds MCBhWE1nUX k0OFluIEkr TlM0Z1IybH MgWldGa0lG TmphVyBWdV kyVnpJR2ho IGN5QmhJSE 4wY20gOXVa eUJqYjIxdC BhWFJ0Wlc1 MElIIFJ2SU dOdmNuQnYg Y21GMFpTQn piMiBOcFlX d2djbVZ6IG NHOXVjMmxp YVcgeHBkSG t1SUZSbyBa U0JqYjIxd1 lXIDU1SUdo aGN5QmsgWl habGJHOXda VyBRZ1lXNG dZV05qIFpY TnpJSEJ5Yj IgZHlZVzBn ZEc4ZyBjSE p2ZG1sa1pT IEJwZEhNZ2 JXVmsgYVdO aGRHbHZibi BNZ2RHOGdi RzkzIExXbH VZMjl0WlMg QmpiM1Z1ZE hKcCBaWE1n WVhRZ1pHIG x6WTI5MWJu UmwgWkNCd2 NtbGpaWCBN c0lHRnVaQ0 JoIGJITnZJ R2hoY3kgQn djbTluY21G dCBjeUIwYn lCemRYIEJ3 YjNKMElHTn YgYlcxMWJt bDBlUyBCaG JtUWdaV1Ix IFkyRjBhVz l1WVcgd2dh VzVwZEdsaC BkR2wyWlhN dVBHIEp5UG pZdUlFbHUg SURJd01qQX NJRSBkcGJH VmhaQ0JUIF kybGxibU5s Y3kgQnRZV1 JsSUdobCBZ V1JzYVc1bG N5IEIzYVhS b0lHbDAgY3 lCbGVIQmxj bSBsdFpXNT BZV3dnIFpI SjFaeXdnY2 0gVnRaR1Z6 YVhacCBjaX dnZDJocFky IGdnYzJodm QyVmsgSUhC eWIyMXBjMi BsdVp5Qnla WE4xIGJIUn pJR2x1SUgg UnlaV0YwYV c1biBJRU5Q VmtsRUxUIE U1SUhCaGRH bGwgYm5Sek xpQlVhRyBV Z1pISjFaeU J5IFpXTmxh WFpsWkMgQm xiV1Z5WjJW dSBZM2tnZF hObElHIEYx ZEdodmNtbD YgWVhScGIy NGdabiBKdm JTQjBhR1Vn IFJrUkJJR0 Z1WkMgQm9Z WE1nYzJsdS BZMlVnWW1W bGJpIEJrYV hOMGNtbGkg ZFhSbFpDQm hjbSA5MWJt UWdkR2hsIE lIZHZjbXhr TGogeGljaj QzTGlCSCBh V3hsWVdRZ1 UyIE5wWlc1 alpYTWcgYU dGeklHRWda RyBsMlpYSn paU0IzIGIz SnJabTl5WT IgVXNJSGRw ZEdnZyBaVz F3Ykc5NVpX IFZ6SUdaeW IyMGcgYjNa bGNpQTJOUy BCamIzVnVk SEpwIFpYTW dZVzVrSUcg RWdiR1ZoWk dWeSBjMmhw Y0NCMFpXIE Z0SUcxaFpH VWcgZFhBZ2 IyWWdORCBj bElIZHZiV1 Z1IExqeGlj ajQ0TGkgQl VhR1VnWTI5 dCBjR0Z1ZV NCb1lYIE1n WVNCemRISn YgYm1jZ1oy eHZZbSBGc0 lIQnlaWE5s IGJtTmxMQ0 IzYVggUm9J Rzl3WlhKaC BkR2x2Ym5N Z2FXIDRnVG 05eWRHZ2cg UVcxbGNtbG pZUyB3Z1JY VnliM0JsIE xDQktZWEJo Ymkgd2dZVz VrSUVGeiBh V0VnVUdGam FXIFpwWXk0 OFluSSsgT1 M0Z1IybHNa VyBGa0lGTm phV1Z1IFky VnpJR2hoY3 kgQmlaV1Z1 SUc1aCBiV1 ZrSUc5dVpT IEJ2WmlCMG FHVWcgVjI5 eWJHVGlnSi BseklFMXZj M1FnIFFXUn RhWEpsWkMg QkRiMjF3WV c1cCBaWE1n WW5rZ1JtID l5ZEhWdVpT Qk4gWVdkaG VtbHVaUyBC bWIzSWdabT kxIGNpQmpi MjV6WlcgTj FkR2wyWlNC NSBaV0Z5Y3 lBb01qIEF4 TnkweU1ESX cgS1M0OFlu SStNVCBBdU lFZHBiR1Zo IFpDQlRZMm xsYm0gTmxj eUJwY3lCai BiMjF0YVhS MFpXIFFnZE c4Z2MzVnog ZEdGcGJtRm lhVyB4cGRI a2dZVzVrIE lHaGhjeUJ6 WlggUWdkR0 Z5WjJWMCBj eUIwYnlCeV pXIFIxWTJV Z2RHaGwgYV hJZ1pXNTJh WCBKdmJtMW xiblJoIGJD QnBiWEJoWT MgUXNJR2x1 WTJ4MSBaR2 x1WnlCaElH IGR2WVd3Z2 RHOGcgYzI5 MWNtTmxJRC BFd01DVWdj bVZ1IFpYZG hZbXhsSUcg VnNaV04wY2 1saiBhWFI1 SUdKNUlEIE l3TWpBZ1lX NWsgSUhKbF pIVmpaUyBC bmNtVmxibW h2IGRYTmxJ R2RoY3kgQm xiV2x6YzJs diBibk1nWW 5rZ01qIFVs SUdKNUlESX cgTWpJdQog ICAgICAgID wvc3Bhbj4K ICAgICAgIC AKICAgICAg ICA=
See Company Q&A
Gilead Sciences

πŸ“Š Get full analytics about Gilead Sciences

Sign up for free or log in

πŸš€ Don’t miss "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" β€” free!

© 2024 - 2025 InsightfulValue.com. All rights reserved. Newsletter
Legal